secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2023-05-19T23:59:59+00:00
Accession:  0000950170-23-023257
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 5.03, 5.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma stockholders approve doubling of authorized shares and equity plan increase
--------------------------------------------------------------------------------

- Authorized common shares increased from 85M to 170M via Charter Amendment filed May 18, 2023.
- 2015 Stock Plan share reserve increased by 4M shares to 7,711,868 (post-reverse split).
- Two Class II directors elected: Timothy P. Coughlin and Jane A. Gross, Ph.D., until 2026.
- Ernst & Young ratified as independent auditor for FY 2023 with 44.5M votes for.
- Advisory say-on-pay compensation approved with 37.2M for, 1.0M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023023257/0000950170-23-023257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023023257/life-20230517.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-023257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer